Artelo Biosciences, Inc.
$4.53
▼
-10.2%
2026-04-21 05:24:00
artelobio.com
NCM: ARTL
Explore Artelo Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.96 M
Current Price
$4.53
52W High / Low
$85.8 / $2.96
Stock P/E
—
Book Value
$-1.89
Dividend Yield
—
ROCE
917.46%
ROE
-16.25%
Face Value
—
EPS
$-37.56
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
7
Beta
0.41
Debt / Equity
-0.53
Current Ratio
0.17
Quick Ratio
0.17
Forward P/E
-6.76
Price / Sales
—
Enterprise Value
$4.29 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Fennec Pharmaceuticals Inc. | $6.73 | — | $232.02 M | — | -10.57% | -65.82% | $9.92 / $5.02 | $1.04 |
| 2. | Satellos Bioscience Inc. | $7.83 | — | $248.1 M | — | -95.23% | -66.37% | $18.98 / $6.24 | $1.8 |
| 3. | XBiotech Inc. | $2.51 | — | $78.32 M | — | -39.17% | -28.23% | $3.61 / $2.09 | $4.6 |
| 4. | Nautilus Biotechnology, Inc. | $2.96 | — | $383.49 M | — | -36.49% | -32.27% | $4.31 / $0.62 | $1.24 |
| 5. | Erasca, Inc. | $21.71 | — | $5.91 B | — | -35.74% | -33.27% | $19.78 / $1.06 | $1.14 |
| 6. | Biohaven Ltd. | $10.82 | — | $1.65 B | — | -222.16% | -3.11% | $24.06 / $7.48 | $0.39 |
| 7. | CytomX Therapeutics, Inc. | $4.89 | — | $1.06 B | — | -21.31% | -35.25% | $8.21 / $0.61 | $0.58 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.79 M | -3.09 M | -3.15 M | -2.38 M | -3.81 M | — |
| Net Profit | -4.17 M | -3.12 M | -3.22 M | -2.37 M | -3.78 M | — |
| EPS in Rs | -5.1 | -3.82 | -3.94 | -2.9 | -4.62 | -2.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -11.4 M | -10.11 M | -9.93 M | -10.29 M |
| Net Profit | -12.88 M | -9.83 M | -9.29 M | -10.08 M |
| EPS in Rs | -15.76 | -12.03 | -11.37 | -12.34 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.8 M | 4.7 M | 13.04 M | 20.42 M |
| Total Liabilities | 4.07 M | 1.84 M | 1.29 M | 1.02 M |
| Equity | -1.27 M | 2.86 M | 11.75 M | 19.4 M |
| Current Assets | 0.69 M | 2.56 M | 10.98 M | 18.32 M |
| Current Liabilities | 4.04 M | 1.77 M | 1.29 M | 1 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -8.52 M | -8.35 M | -8.21 M | -8.01 M |
| Investing CF | -0.06 M | 7.77 M | 3.51 M | 2.96 M |
| Financing CF | 6.87 M | 0.11 M | 0.57 M | 0 M |
| Free CF | -8.52 M | -8.35 M | -8.21 M | -8.01 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -5.78% | 7.87% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-03-10 | 1:0.333333 |
| 2025-06-13 | 1:0.166667 |
| 2022-08-10 | 1:0.0666667 |